Vitamin D is a group of steroid compounds soluble in fats. Vitamin D has powerful, pleiotropic effects all over the human body. It is synthesized in human skin, but can also be found in dietary supplements and fortified foods. Vitamin D receptors (VDR) can be found in many tissues, as well as in the female reproductive tract \[[@cit0001], [@cit0002]\]. According to recent reports, it is believed that vitamin D has a beneficial effect on lowering the risk of various diseases, e.g. multiple forms of cancer, diabetes, cardiovascular diseases, metabolic syndrome, multiple sclerosis, inflammatory bowel diseases and uterine fibroids \[[@cit0001]--[@cit0006]\]. Vitamin D regulates cell proliferation and differentiation, inhibits angiogenesis and stimulates apoptosis \[[@cit0001], [@cit0002], [@cit0004], [@cit0005]\]. Vitamin D levels are mostly measured using serum 25-hydroxyvitamin D (25(OH)D) concentration, which is considered to be the best known marker of vitamin D obtained through both diet and body synthesis. According to Holick, the vitamin D level should be higher than 30 ng/ml \[[@cit0001]\].

Ethinylestradiol (EE2) is a derivative of 17β-estradiol (E2), the major endogenous human estrogen. EE2 is used in many forms of combined oral contraception (COC) and is one of the most commonly used medications for this purpose. Ethinylestradiol is hormonally effective by activating the estrogen receptor and thus exerts its estrogenic effects \[[@cit0007]\].

Drospirenone is a steroidal progestin (of the spironolactone group) used in contraception and hormonal replacement therapy. It is also an aldosterone antagonist with potassium-sparing properties. It is an agonist of the progesterone receptor and an antagonist of the mineralocorticoid and androgen receptors, and hence a progestagen, antimineralocorticoid and antiandrogen. Drospirenone does not present any estrogenic or glucocorticoid or antiglucocorticoid activity. It has a potent antigonadotropic effect at sufficient dosages as a result of progesterone receptor activation. It has been stated that drospirenone has a pharmacological profile that is closely related to that of natural progesterone \[[@cit0008]\]. Drospirenone is about ten times more potent as an antimineralocorticoid in comparison to spironolactone \[[@cit0008]--[@cit0010]\]. The drospirenone antimineralocorticoid activity promotes sodium excretion and prevents water retention \[[@cit0010]\].

It is believed that contraceptives containing estrogens or estrogens combined with progestins may affect 25(OH)D serum concentrations. There is a lack of reports in this field, but some of them have noted a significant difference in 25(OH)D concentrations among women using COC compared to controls. Available literature suggests that the use of COC may have a beneficial effect in increasing 25(OH)D serum levels, but unfortunately it does not specify the exact composition of the contraceptive pill \[[@cit0011]--[@cit0014]\]. However, a very recent Turkish study demonstrated that the use of COC in polycystic ovary syndrome (PCOS) patients may decrease 25(OH)D levels. In the cited study the authors opine that the reason for lower vitamin D concentrations could be related to PCOS or be explained by the low 25(OH)D levels throughout Turkish society, especially in the adult female group \[[@cit0015]\].

The objective of the study was to investigate the influence of COC containing EE2 and drospirenone on 25-hydroxyvitamin D serum concentration in women. All patients included in the study provided voluntary informed consent. The patients were recruited in a gynecological clinic from the group of patients without identified chronic diseases during their visits. The sample was limited to premenopausal women who were not pregnant or breastfeeding, had no history of cancer, ovarian removal or hysterectomy, and were not using any form of estrogen and progestin other than the EE2 and drospirenone combined oral pill (in the research group). Selected patients were non-smokers who stated that their diet was healthy and their usual physical activity was normal. Patients were not using any additional dietary supplements. The study included a total of 54 healthy Caucasian woman between 21 and 46 years old from the Mazowieckie and Lubelskie regions in Poland. Twenty-one of them were using combined oral contraception (0.02 or 0.03 mg ethinyloestradiol with 3 mg drospirenone). Patients from the COC group had been using contraception for a minimum of 3 months. In this group the contraception was prescribed for standard registered purposes. Patients from the non-COC group had not used any hormonal form of contraception for at least 3 months. Patients were recruited from September 2014 until May 2015 (not in summer). Standard anthropometric data were obtained from each subject. Weight and height measurements were performed and body mass index (BMI) was calculated for each patient. Venous blood samples were collected from all patients for biochemical analysis. Serum 25(OH)D was measured by a 25(OH)D ELISA kit, Biovendor REA 300/96 (supplied by DLD, Diagnostika GMBH). According to our knowledge the serum level of 25-hydroxyvitamin D is the best indicator of human vitamin D status. An Epoch microplate analyzer (BioTek, USA) was used for ELISA. Inter- and intra-assay coefficients of variation were 5.1% and 3.2%, respectively.

The values of the parameters measured on a quotient scale were characterized using mean, median, standard deviation and range of variability. To detect the existence of differences in quantitative traits between the two analyzed groups, Student's *t*-test with the grouping variable was used. The level of *p* \< 0.05 indicated the existence of a statistically significant dependence or difference. Statistical analysis was performed with Statistica 12.0 software (StatSoft, Poland).

38.9% (*n* = 21) of all patients were using the combined oral contraceptive pill and formed the COC research group, while 61.1% (*n* = 33) were non-COC patients (controls). COC patients' age ranged from 24 to 46 years (half of the patients were older than 35 years -- Me = 35); the mean age was 34.48 ±7.22 years. Non-COC patients' age ranged from 21 to 46 years (half of the patients were older than 32 years -- Me = 32); the mean age was 33.94 ±7.51 years. The obtained results were statistically insignificant (Student's *t*-test: *t* = 0.26; d*f* = 52; *p* = 0.80).

The COC patients' BMI ranged from 18.94 kg/m^2^ to 29.39 kg/m^2^ (half of the patients had BMI higher than 22.49 kg/m^2^ -- Me = 22.49); the mean BMI value was 23.67 ±3.42 kg/m^2^. Non-COC patients' BMI ranged from 18.38 kg/m^2^ to 28.60 kg/m^2^ (half of the patients had BMI higher than 22.72 kg/m^2^ -- Me = 22.72); the mean BMI value was 23.60 ±3.10 kg/m^2^. The obtained results were statistically insignificant (Student's *t*-test: *t* = 0.07; d*f* = 52; *p* = 0.94).

The COC patients' 25(OH)D serum concentrations ranged from 12.02 ng/ml to 49.78 ng/ml, half of the patients had a 25(OH)D serum concentration higher than 28.51 ng/ml (Me = 28.51). Mean 25(OH)D concentration was 30.69 ±11.82 ng/ml. Non-COC patients' 25(OH)D serum concentrations ranged from 9.24 ng/ml to 51.12 ng/ml; half of the controls had a 25(OH)D serum concentration higher than 18.61 ng/ml (Me = 18.61). Mean 25(OH)D concentration was 22.08 ±10.54 ng/ml. Comparative analysis demonstrated that mean vitamin D serum concentration differed significantly between groups (Student's *t*-test: *t* = 2.79; d*f* = 52; *p* = 0.007). The mean 25(OH)D serum concentration in women who used COC was higher than the mean 25(OH)D serum concentration in controls. Results are presented in [Table I](#t0001){ref-type="table"} and [Figure 1](#f0001){ref-type="fig"}.

###### 

25-hydroxyvitamin D serum levels in both groups

  Group       25-hydroxyvitamin D \[ng/ml\]           
  ----------- ------------------------------- ------- --------------
  COC         12.02--49.78                    28.51   30.69 ±11.82
  Non-COC     9.24--51.12                     18.61   22.08 ±10.54
  *P-*value                                   0.007   
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The majority of available data define vitamin D insufficiency as 25(OH)D levels of 20--29.9 ng/ml. Deficiency is defined when the level is under 20 ng/ml. An acceptable vitamin D level should be at least 30 ng/ml \[[@cit0001]\]. Previous studies have reported that oral contraceptive use can increase 25(OH)D serum levels. The prevalence of vitamin D deficiency is lower among COC users compared with controls. There is a study that evaluated the relationship between vitamin D and genetic and environmental determinants. It reported a positive correlation between the use of COC and higher 25(OH)D serum levels \[[@cit0012], [@cit0013], [@cit0016]\].

Results obtained in this study suggest that EE2 and drospirenone OC use is associated with higher vitamin D levels in the healthy patient group. Both groups were very similar and did not differ statistically in age or BMI. The literature is limited in assessment of oral contraception use and vitamin D metabolism. Our findings are similar to the results obtained by other researchers in the past \[[@cit0012], [@cit0013]\]. Further research is necessary to examine the relationship of the effect of COC on vitamin D metabolism, as well as the biological cause of this mechanism. It is still unclear whether the type of COC composition changes the 25(OH)D metabolism.

Our findings are encouraging to conduct further research in this field. The obtained results should be verified in larger groups, and in the case of positive results the next step should be performed with blinded trials. The main task is to investigate which of the OC components have the major effect on the increase of serum 25(OH)D level. In the study performed by Schreurs *et al.* no significant differences were found between the reference group and the group using oral contraceptives with EE2 concentrations of 0.05 mg or 0.03 mg \[[@cit0017]\]. Because of that, it can be suggested that the 25(OH)D levels are not influenced by the different estrogenic concentrations. Is therefore drospirenone the component corresponding with increased concentrations of vitamin D? A known fact about vitamin D and the renin-angiotensin-aldosterone system (RAAS) is that VDR complex inhibits renin expression *in vitro*. It is believed that insufficient vitamin D status is associated with increased renin activity. The proper supplementation of vitamin D can downregulate the RAAS \[[@cit0018]--[@cit0020]\]. Some of the studies demonstrated an association between vitamin D metabolites and components of the RAAS. 25(OH)D levels inversely correlate with renin activity in plasma as well as with elevated circulating levels of angiotensin II \[[@cit0018]--[@cit0020]\]. Some data suggest that angiotensin II may have an effect on osteoblastic differentiation and expression of osteogenesis-related transcription factors \[[@cit0021]\]. There are also studies about the effect of spironolactone on improving vitamin D metabolism (changes in kidney gene expression) \[[@cit0022]\]. Drospirenone-associated metabolic pathways affecting vitamin D metabolism require additional studies. While the pharmaceutical market is receiving a new form of contraception based only on drospirenone, it may be interesting that apart from the other advantages, it may also have a beneficial effect on patients' vitamin D status \[[@cit0023]\] and be a suitable OC option in 25(OH)D insufficient patients. According to our latest results, if drospirenone contraception were proven to raise the vitamin D serum level, this could also be a good choice for patients at high risk of uterine fibroids \[[@cit0024], [@cit0025]\].

The main conclusion of this study is that the use of COC increases the circulating levels of 25(OH)D in premenopausal, healthy, adult women. This is the first study revealing the potential effect of COC with EE2 and drospirenone on the serum 25(OH)D levels in women. In our data this form of contraception increased circulating 25(OH) levels. Therefore this COC can also be considered in some groups of patients as a potential addition to vitamin D supplementation in the deficiency group or in the deficiency high risk group. Further research on larger groups is necessary to determine the exact role of both EE2 and drospirenone in vitamin D metabolism. A properly constructed randomized control trial would answer most of the unknown aspects.

All of the STROBE guidelines were indicated in the preparation of this manuscript.

Conflict of interest
====================

The authors declare no conflict of interest.
